Qsemble Capital Management LP Decreases Stock Position in IQVIA Holdings Inc. (NYSE:IQV)

Qsemble Capital Management LP lessened its position in IQVIA Holdings Inc. (NYSE:IQV) by 44.4% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,562 shares of the medical research company’s stock after selling 1,245 shares during the quarter. Qsemble Capital Management LP’s holdings in IQVIA were worth $395,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. QRG Capital Management Inc. lifted its position in shares of IQVIA by 9.3% in the first quarter. QRG Capital Management Inc. now owns 5,331 shares of the medical research company’s stock valued at $1,348,000 after acquiring an additional 452 shares in the last quarter. Tranquility Partners LLC lifted its position in shares of IQVIA by 0.3% in the first quarter. Tranquility Partners LLC now owns 16,685 shares of the medical research company’s stock valued at $4,219,000 after acquiring an additional 57 shares in the last quarter. Inspire Investing LLC lifted its position in shares of IQVIA by 13.8% in the first quarter. Inspire Investing LLC now owns 22,114 shares of the medical research company’s stock valued at $5,592,000 after acquiring an additional 2,678 shares in the last quarter. Inspire Advisors LLC lifted its position in shares of IQVIA by 11.8% in the first quarter. Inspire Advisors LLC now owns 2,200 shares of the medical research company’s stock valued at $556,000 after acquiring an additional 233 shares in the last quarter. Finally, Meeder Advisory Services Inc. lifted its position in shares of IQVIA by 5.7% in the first quarter. Meeder Advisory Services Inc. now owns 3,148 shares of the medical research company’s stock valued at $796,000 after acquiring an additional 169 shares in the last quarter. Hedge funds and other institutional investors own 89.62% of the company’s stock.

Analyst Upgrades and Downgrades

IQV has been the topic of a number of analyst reports. Evercore ISI reduced their price objective on IQVIA from $250.00 to $230.00 and set an “outperform” rating on the stock in a research report on Tuesday, July 9th. StockNews.com raised IQVIA from a “hold” rating to a “buy” rating in a research note on Monday. Robert W. Baird dropped their price objective on IQVIA from $241.00 to $235.00 and set a “neutral” rating for the company in a research note on Wednesday, July 10th. Barclays decreased their price target on IQVIA from $275.00 to $255.00 and set an “overweight” rating for the company in a report on Friday, June 28th. Finally, The Goldman Sachs Group started coverage on IQVIA in a report on Thursday, June 6th. They issued a “buy” rating and a $270.00 target price for the company. Three equities research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company’s stock. According to MarketBeat, IQVIA presently has an average rating of “Moderate Buy” and an average target price of $255.73.

IQVIA Stock Performance

NYSE IQV traded up $0.97 on Wednesday, hitting $233.94. 339,119 shares of the company’s stock were exchanged, compared to its average volume of 1,062,270. The company has a debt-to-equity ratio of 2.02, a current ratio of 0.88 and a quick ratio of 0.88. The firm’s 50-day moving average price is $219.77 and its two-hundred day moving average price is $228.92. IQVIA Holdings Inc. has a fifty-two week low of $167.42 and a fifty-two week high of $261.73. The firm has a market cap of $42.62 billion, a price-to-earnings ratio of 31.82, a P/E/G ratio of 2.06 and a beta of 1.49.

IQVIA (NYSE:IQV) last released its quarterly earnings data on Thursday, May 2nd. The medical research company reported $2.30 earnings per share for the quarter, beating the consensus estimate of $2.19 by $0.11. IQVIA had a return on equity of 29.17% and a net margin of 9.01%. The firm had revenue of $3.74 billion during the quarter, compared to the consensus estimate of $3.69 billion. On average, research analysts expect that IQVIA Holdings Inc. will post 10.11 EPS for the current year.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.